

## 2024 Elderplan Part B Step Therapy Program

In certain cases, Elderplan may require you to try a **Step 1 (Preferred) Drug** to treat your medical condition before proceeding to a **Step 2 (Non-Preferred) Drug**. Our Step 1 (Preferred) Drugs promote therapeutic effectiveness and are low in drug cost.

Part B Drug Step Therapy does **not** apply to you if you have already been receiving treatment with a Non-Preferred Drug in the past 365 days. If you are new to treatment, and your provider determines that a Non-Preferred Drug is the best fit for you, your provider may request a Non-Preferred Part B Drug at this fax number **929-275-3223**.

The table below displays the drug classes included in Elderplan's Part B Drug Step Therapy Program. \*

Drug Class	Step 1 Drugs (Preferred)	Step 2 Drugs (Non-Preferred)
<p align="center"><b>Hematologic, Neutropenia Colony Stimulating Factors – Long Acting</b></p>	<p align="center">Fulphila Neulasta</p>	<p align="center">Fylnetra, Nyvepria, Rolvedon Stimufend, Udenyca, Ziextenzo</p>
<p align="center"><b>Hematologic, Neutropenia Colony Stimulating Factors – Short Acting</b></p>	<p align="center">Zarxio</p>	<p align="center">Granix Leukine Neupogen Nivestym Releuko</p>
<p align="center"><b>Trastuzumab</b></p>	<p align="center">Kanjinti Trazimera</p>	<p align="center">Herceptin Herceptin Hylecta Herzuma, Ogivri, Ontruzant</p>

\* This Part B Drug list may be subject to change throughout the year. Non-preferred product(s) are only available if process exception criteria are met. This list indicates the common uses for which the drug is prescribed. Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with Elderplan. The listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes.

Effective 01/01/2024